Positive association of serum levels of pigment epithelium-derived factor with high-sensitivity C-reactive protein in apparently healthy unmedicated subjects

Journal of International Medical Research

Volumn 38, Issue 2, 2010, Pages 443-448

  Umei, H ^a   Yamagishi, S I ^a   Imaizumi, T ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

High sensitivity C reactive protein (HS CRP); Pigment epithelium derived factor (PEDF); Subclinical inflammation

Indexed keywords

C REACTIVE PROTEIN; CREATININE; PIGMENT EPITHELIUM DERIVED FACTOR; TRIACYLGLYCEROL;

ADULT; ANAMNESIS; ANTHROPOMETRY; ARTICLE; BLOOD CHEMISTRY; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; JAPANESE; KIDNEY FUNCTION; MALE; NORMAL HUMAN; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77953728438     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800207     Document Type: Article

References (18)

1. Tombran-Tink J, Chader GG, Johnson LV: PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53: 411-414.
2. Yamagishi S, Nakamura K, Ueda S, et al Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxldative mechanism of PEDF. Cell Tissue Res 2005; 320: 437-445.
3. Yamagishi S, Nakamura K, Matsui T, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006; 281: 20213-20220.
4. Zhang SX, Wang JJ, Gao G, et al. Pigment epithelium-derived factor (PEDF) is an endogenous anti-inflammatory factor. FASEB J 2006; 20: 323-325.
5. Nakamura K, Yamagishi S, Matsui T, et al. Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 2007; 170:2159-2170.
6. Yamagishi S, Matsui T, Nakamura K: Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders. Curr Pharm Des 2009; 15: 1027-1033.
7. Yamagishi S, Adachi H, Abe A, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 2447-2450.
8. Ridker PM, Buring IE, Cook NR, et al C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14719 initially healthy American women. Circulation 2003; 107: 391 - 397.
9. Tracy RP, Lemaitre RN, Psaty BM, et al: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vase Biol 1997; 17: 1121-1127.
10. Vlachopoulos C, Rokkas K, Ioakeimidis N, et al: Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol 2007; 52: 1590-1600.
11. Devaraj S, Singh U, Jialal I: Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009; 20: 182-189.
12. Zambon A, Pauletto P, Crepaldi G: Review article: the metabolic syndrome - a chronic cardiovascular inflammatory condition. Aliment Pharmacol Ther 2005; 22(suppl 2): 20-23.
13. Verma S, Szmitko PE, Ridker PM: C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med 2005; 2: 29-36.
14. Motomiya Y, Yamagishi S, Adachi H, et al. Increased serum concentrations of pigment epithelium-derived factor in patients with end-stage renal disease. Clin Chem 2006; 52: 1970-1971.
15. Yoshida T, Yamagishi S, Nakamura K, et al. Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Horm Metab Res 2008; 40: 620-625.
16. Ridker PM on behalf of the JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C reactive protein: rationale and design of the IUPITER trial. Circulation 2003; 108: 2292-2297.
17. Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007; 49: 290-297.
18. Koh KK, Quon MI, Han SH, et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients, Int J Cardiol 2006; 108: 96-100.